Health-Chem Corporation (HCLC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Health-Chem Corporation (HCLC) trades at $0.00 with AI Score 38/100 (Grade D). Health-Chem Corporation, through Transderm Laboratories, specializes in transdermal drug delivery systems, including nitroglycerin patches for angina pectoris. Market cap: $73,985, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for HCLC: HCLC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HCLC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HCLC: 1/1 perspectives are bearish.
How is this calculated? →Health-Chem Corporation (HCLC) Healthcare & Pipeline Overview
Health-Chem Corporation, via its Transderm Laboratories subsidiary, is a U.S.-based developer and manufacturer of transdermal drug delivery systems, notably nitroglycerin patches for angina pectoris. The company also provides contract R&D services, distributing products through a multifaceted sales network to pharmacies, hospitals, and managed care organizations.
What Is the Investment Thesis for HCLC?
Health-Chem Corporation (HCLC), operating through Transderm Laboratories, specializes in the research, development, manufacturing, and commercialization of transdermal drug delivery systems, with a key product being nitroglycerin patches for angina pectoris. The company's business model is further strengthened by offering contract research and development services to third parties, leveraging its specialized expertise and infrastructure. While HCLC currently operates with a negative profit margin of -27.9% and a gross margin of 9.8%, indicating operational challenges, its focus on a specific drug delivery technology presents a defined market niche. The transdermal drug delivery market is characterized by patient preference for non-invasive methods and potential for improved compliance, which could serve as a long-term value driver. Growth catalysts for HCLC could include successful expansion of its contract R&D services, securing new third-party agreements, or potential product line extensions within the transdermal space, assuming regulatory approvals. The company's established distribution network, encompassing wholesalers, major retail chains, and healthcare institutions, provides a foundation for market penetration. However, the company's current market capitalization of 74K and its OTC Other tier listing suggest significant liquidity and valuation challenges. The highly negative Beta of -26.02 indicates extreme volatility and an inverse correlation to market movements, which warrants careful consideration. Future performance will depend on its ability to improve profitability, potentially through increased sales volume of its existing products or successful commercialization of new transdermal applications.
Based on FMP financials and quantitative analysis
HCLC Key Highlights
- Market Capitalization: $0.00B, reflecting a micro-cap or non-reporting status.
- Profit Margin: -27.9%, indicating current unprofitability from operations.
- Gross Margin: 9.8%, suggesting a low margin on product sales relative to cost of goods sold.
- Employee Base: 55 employees, highlighting a relatively small operational footprint.
- Beta: -26.02, an exceptionally high negative beta suggesting extreme volatility and inverse correlation to market movements.
Who Are HCLC's Competitors?
HCLC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HCLC's Key Strengths?
- Specialized focus and expertise in transdermal drug delivery systems.
- Established product (nitroglycerin patches) addressing a significant medical need.
- Diversified revenue potential through contract R&D services.
- Extensive direct and indirect distribution network across the U.S.
What Are HCLC's Weaknesses?
- Negative profit margin (-27.9%) and low gross margin (9.8%).
- Limited product portfolio primarily centered on one core product type.
- Small market capitalization ($0.00B) and OTC Other listing imply limited access to capital and liquidity.
- High negative Beta (-26.02) indicates extreme market sensitivity and potential for significant value fluctuations.
What Could Drive HCLC Stock Higher?
- Potential for new contract research and development agreements with third-party pharmaceutical companies, expanding service revenue streams.
- Any future regulatory approvals for new transdermal drug delivery systems, either proprietary or for clients, could open new market opportunities.
- Continued market penetration and distribution expansion for existing transdermal nitroglycerin patches through its established network of pharmacies and healthcare providers.
- Strategic partnerships or licensing agreements that could provide capital infusion or broader market access for its specialized technology.
What Are the Key Risks for HCLC?
- Financial-distress signal — its Altman Z-Score of -9.49 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant liquidity risk due to its OTC Other tier listing and unknown disclosure status, making it difficult for investors to trade shares efficiently.
- Persistent unprofitability, as evidenced by a -27.9% profit margin, indicating challenges in achieving sustainable financial performance.
- Intense competition from larger pharmaceutical companies with greater R&D budgets and market reach in the drug delivery sector.
- Regulatory hurdles and compliance costs inherent in the pharmaceutical industry, which can impact product development and market access.
- Dependence on a relatively mature product (nitroglycerin patches) and the need for successful diversification or new product development to drive future growth.
What Are the Growth Opportunities for HCLC?
- Expansion of Contract Research and Development Services: Health-Chem Corporation's offering of contract R&D services to third-party clients represents a significant growth avenue. The global contract research organization (CRO) market, valued at over $60 billion in 2023, is projected to grow at a CAGR of approximately 9-10% through 2030, driven by increasing R&D outsourcing by pharmaceutical and biotechnology companies. By leveraging its specialized expertise in transdermal drug delivery, HCLC can attract more clients seeking to develop novel patch-based therapies, thereby diversifying its revenue streams and utilizing its existing infrastructure more efficiently. This strategy could provide a more stable revenue base compared to relying solely on proprietary product sales, with potential for new agreements emerging over the next 3-5 years.
- Market Penetration for Transdermal Nitroglycerin Patches: The market for cardiovascular medications, including those for angina pectoris, remains substantial and consistently growing due to an aging population and increasing prevalence of heart conditions. While nitroglycerin patches are a mature product, Health-Chem's established distribution network across wholesalers, retail pharmacies, and healthcare institutions provides a foundation for increasing market share. Focused marketing efforts and strategic partnerships with group purchasing organizations or managed care providers could enhance product visibility and access. Expanding geographic reach within the U.S. or optimizing supply chain efficiencies could also drive sales volume for its core product over the short to medium term (1-3 years).
- Development of New Transdermal Drug Delivery Systems: Leveraging its core competency in transdermal technology, Health-Chem has the opportunity to research and develop new patch-based drug delivery systems for other therapeutic areas beyond cardiovascular health. The transdermal drug delivery market is expanding into pain management, hormone replacement, central nervous system disorders, and diabetes. Identifying unmet needs in these areas and developing proprietary or co-developed patches could unlock new revenue streams. This would require significant R&D investment and navigating regulatory pathways, with a potential timeline for new product commercialization typically spanning 5-10 years, offering long-term growth potential.
- Strategic Partnerships and Licensing Agreements: Collaborating with larger pharmaceutical companies or biotechnology firms could provide Health-Chem with access to broader markets, increased R&D funding, and enhanced commercialization capabilities. Strategic partnerships could involve co-development agreements for new transdermal products, licensing its existing technology, or forming joint ventures to expand manufacturing capacity. Such alliances could accelerate product development cycles, reduce financial risk, and provide immediate market access for its specialized delivery systems. These opportunities could materialize over a 2-5 year horizon, significantly impacting the company's scale and reach.
- Optimization of Manufacturing and Supply Chain: Improving operational efficiencies in manufacturing and supply chain management could lead to cost reductions and improved gross margins, which are currently at 9.8%. Implementing advanced manufacturing technologies, optimizing raw material procurement, or streamlining distribution logistics could enhance profitability. Given the competitive nature of the pharmaceutical industry, even marginal improvements in operational efficiency can significantly impact the bottom line. This internal optimization could be an ongoing process, yielding benefits within a 1-2 year timeframe by improving cost structures and potentially allowing for more competitive pricing or higher profit retention.
What Opportunities Does HCLC Have?
- Expansion of contract R&D services to new pharmaceutical clients.
- Development of new transdermal products for other therapeutic areas.
- Strategic partnerships for co-development or broader market access.
- Optimization of manufacturing and supply chain to improve profitability.
What Threats Does HCLC Face?
- Intense competition from larger pharmaceutical companies with greater resources.
- Strict and evolving regulatory landscape for drug approvals and manufacturing.
- Dependence on a mature product market (nitroglycerin patches).
- Liquidity and informational asymmetry risks associated with OTC Other tier listing.
What Are HCLC's Competitive Advantages?
- Specialized expertise in transdermal drug delivery system research, development, and manufacturing.
- Established regulatory experience and infrastructure for producing pharmaceutical-grade patches.
- Existing distribution network across various U.S. healthcare channels, including major retail and institutional players.
- Proprietary formulations and manufacturing processes for its core products like nitroglycerin patches.
What Does HCLC Do?
Health-Chem Corporation, established in 1970 and headquartered in Emigsville, Pennsylvania, operates primarily through its subsidiary, Transderm Laboratories Corporation. This entity is dedicated to the comprehensive lifecycle of transdermal drug delivery systems, encompassing research, development, manufacturing, and commercialization activities across the United States. A cornerstone of its product portfolio includes transdermal nitroglycerin patches. These patches are specifically engineered to deliver medication through the skin, providing a sustained release that helps alleviate vascular and cardiovascular symptoms associated with angina pectoris, commonly known as chest pain. This specialized product addresses a critical need in cardiovascular health management, offering an alternative delivery method for a well-established therapeutic agent. Beyond its proprietary product development, Health-Chem Corporation extends its expertise to third-party clients by offering contract research and development services. This dual business model allows the company to leverage its scientific and manufacturing capabilities for external partners, potentially diversifying its revenue streams and optimizing asset utilization. The company employs a sophisticated and extensive sales strategy to ensure its products reach a broad market. This involves direct engagement with key players in the pharmaceutical supply chain, including wholesalers, national distributors, and major retail pharmacy chains. Furthermore, it targets mail-order pharmacies and group purchasing organizations, which play significant roles in drug procurement and distribution. Indirectly, Health-Chem Corporation's products permeate the market through a network of independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit management firms. This layered distribution approach ensures wide accessibility of its transdermal solutions across various healthcare settings and patient populations. The company's focus on transdermal technology positions it within a specialized segment of the pharmaceutical industry, emphasizing convenience, patient compliance, and controlled drug release. With 55 employees, Health-Chem Corporation maintains a focused operation dedicated to advancing its niche in drug delivery.
What Products and Services Does HCLC Offer?
- Researches and develops transdermal drug delivery systems.
- Manufactures transdermal patches, including nitroglycerin patches for angina pectoris.
- Commercializes its proprietary transdermal products across the United States.
- Offers contract research and development (R&D) services to other companies.
- Distributes products directly to wholesalers, distributors, and major retail pharmacy chains.
- Sells indirectly through independent pharmacies, hospitals, and managed care organizations.
- Focuses on non-invasive drug delivery methods for various medical conditions.
How Does HCLC Make Money?
- Generates revenue from the sale of proprietary transdermal drug delivery systems, such as nitroglycerin patches.
- Earns income from providing specialized contract research and development services to third-party pharmaceutical clients.
- Utilizes a dual sales strategy, combining direct sales to large distributors and pharmacies with indirect sales through healthcare institutions.
- Leverages its expertise in transdermal technology to serve both its own product pipeline and external R&D needs.
What Industry Does HCLC Operate In?
Health-Chem Corporation operates within the Medical - Diagnostics & Research industry, specifically focusing on the niche segment of transdermal drug delivery systems. This segment is part of the broader pharmaceutical market, which is continuously seeking innovative and patient-friendly drug administration methods. The transdermal patch market is driven by advantages such as improved patient compliance, reduced side effects due to controlled release, and avoidance of first-pass metabolism. Key market trends include the increasing prevalence of chronic diseases requiring long-term medication, a growing elderly population, and a preference for non-invasive drug delivery. Health-Chem's primary product, nitroglycerin patches for angina pectoris, positions it within the cardiovascular therapeutic area, a substantial and ongoing market. The competitive landscape includes larger pharmaceutical companies with diversified drug delivery platforms, as well as specialized transdermal technology firms. Health-Chem's strategy of combining proprietary product development with contract R&D services allows it to participate in both the direct product market and the broader pharmaceutical innovation ecosystem.
Who Are HCLC's Key Customers?
- Wholesalers and national pharmaceutical distributors.
- Prominent retail pharmacy chains and mail-order pharmacies.
- Group purchasing organizations (GPOs) for bulk procurement.
- Independent pharmacies, hospitals, and nursing homes (indirectly).
- Managed care organizations and pharmacy benefit management (PBM) firms.
- Third-party pharmaceutical and biotechnology companies seeking contract R&D services.
Company Profile
Health-Chem Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Emigsville, US. The company is led by CEO Ronald J. Burghauser. HCLC has traded publicly since 1972.
How Health-Chem Corporation Is Valued
Health-Chem Corporation carries a market capitalization of 74K, placing it in the micro-cap category. Relative to its peer group, HCLC's quantitative score of 38/100 is below the peer average of 64/100.
ROE 11%Key Financial Metrics
Return on equity for Health-Chem Corporation stands at 10.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -28.6%, showing how much profit it generates from its asset base. A current ratio of 0.20 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 3/9Financial Health
Health-Chem Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.49 places it in the distress zone, a signal of elevated financial risk.
HCLC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests that those closest to the company see value, a potential signal of future growth or stability.
- Positive community sentiment indicates a growing belief in the company's long-term prospects and management's vision.
- The company's niche focus in specialized chemical solutions may provide resilience against broader economic downturns, attracting investors seeking stability.
- Increased market awareness of Health-Chem's innovative product line is generating excitement among potential customers and investors.
Bear Case
- Limited market liquidity could lead to increased volatility and difficulty in executing large trades, deterring institutional investors.
- Negative community chatter raises concerns about potential operational challenges or shifts in market dynamics impacting the company.
- Dependence on a small number of key clients creates vulnerability if those relationships weaken or dissolve, affecting revenue streams.
- Increasing competition in the specialty chemical sector could erode market share and pressure profit margins, impacting long-term growth potential.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
HCLC Latest News
No recent news available for HCLC.
HCLC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HCLC.
Price Targets
Wall Street price target analysis for HCLC.
HCLC MoonshotScore
What does this score mean?
The MoonshotScore rates HCLC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ronald J. Burghauser
Chief Executive Officer
Ronald J. Burghauser leads Health-Chem Corporation, overseeing its operations and strategic direction. His role involves managing a team of 55 employees dedicated to the research, development, manufacturing, and commercialization of transdermal drug delivery systems. While specific details regarding his prior career history, educational background, and previous executive roles are not provided in the source data, his position indicates a leadership capacity within the healthcare and pharmaceutical sector, particularly in specialized drug delivery technologies. His responsibilities encompass both the proprietary product line and the contract research and development services offered by the company.
Track Record: Under Ronald J. Burghauser's leadership, Health-Chem Corporation continues its focus on transdermal drug delivery, maintaining the production and distribution of key products like nitroglycerin patches. His tenure involves navigating the operational aspects of a specialized pharmaceutical company, including managing its 55-person workforce and overseeing its multifaceted sales strategy. The company's continued operation since its founding in 1970, with its current focus, reflects ongoing management of its core business.
HCLC OTC Market Information
Health-Chem Corporation (HCLC) trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which adhere to stringent listing standards regarding financial reporting, minimum share price, and corporate governance, OTC Other companies have minimal public disclosure requirements. This tier is typically for companies that do not meet the standards for OTCQX or OTCQB, or that choose not to provide current information. This classification implies higher risk for investors due to limited transparency and oversight compared to exchange-listed or even higher-tier OTC securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Extreme liquidity risk due to low trading volume and wide bid-ask spreads.
- Significant informational asymmetry stemming from unknown disclosure status and less stringent reporting.
- High volatility, as indicated by an exceptionally negative Beta of -26.02.
- Limited access to capital markets for funding growth or operational needs.
- Potential for price manipulation given the lack of oversight and transparency.
- Verify any available financial statements directly from the company or third-party sources.
- Research any news or press releases issued by the company, however infrequent.
- Investigate the company's management team beyond publicly available information.
- Assess the actual market for its specific products (transdermal nitroglycerin patches).
- Examine any historical trading data for patterns in volume and price.
- Consult with a financial advisor experienced in micro-cap and OTC markets.
- Understand the regulatory environment for its products and operations.
- Established founding year of 1970, indicating a long operational history.
- Identifiable physical headquarters in Emigsville, Pennsylvania.
- Clear description of products (transdermal nitroglycerin patches) and services (contract R&D).
- Identified CEO, Ronald J. Burghauser, managing 55 employees.
- Specific distribution channels mentioned (wholesalers, retail chains, hospitals).
HCLC Healthcare Stock FAQ
What does Health-Chem Corporation do?
Health-Chem Corporation, through its subsidiary Transderm Laboratories Corporation, specializes in the entire lifecycle of transdermal drug delivery systems within the United States. This encompasses the research, development, manufacturing, and commercialization of patches designed to deliver medication through the skin. A primary product is transdermal nitroglycerin patches, used to manage symptoms of angina pectoris. Additionally, the company offers its specialized expertise as a service, providing contract research and development to other pharmaceutical and biotechnology firms. Its products reach the market via a comprehensive network including direct sales to wholesalers and major retail pharmacies, and indirect distribution through hospitals, nursing homes, and managed care organizations.
What revenue streams does Health-Chem Corporation have in healthcare?
Health-Chem Corporation primarily generates revenue from two distinct streams within the healthcare sector. The first is through the sale of its proprietary transdermal drug delivery systems, most notably its transdermal nitroglycerin patches. These products are commercialized across the United States, reaching end-users through a multifaceted distribution network that includes direct sales to wholesalers, large retail pharmacy chains, mail-order pharmacies, and group purchasing organizations, as well as indirect sales through independent pharmacies, hospitals, and managed care organizations. The second significant revenue stream comes from offering contract research and development (R&D) services to third-party clients. This allows other pharmaceutical companies to leverage Health-Chem's specialized expertise and facilities in transdermal technology for their own product pipelines, providing a diversified income source.
How does Health-Chem Corporation navigate regulatory approval processes?
While specific details on Health-Chem Corporation's regulatory track record or pending approvals are not provided, as a company operating in the pharmaceutical sector in the United States, it must adhere to stringent regulations set forth by the U.S. Food and Drug Administration (FDA). This involves rigorous testing and documentation for the safety, efficacy, and quality of its transdermal drug delivery systems, including its nitroglycerin patches. The development and commercialization of any new transdermal product, whether proprietary or for a contract client, would necessitate navigating complex Investigational New Drug (IND) applications, clinical trials, and New Drug Applications (NDA) or Abbreviated New Drug Applications (ANDA) for generic versions. Compliance strategy would involve maintaining Good Manufacturing Practices (GMP) for its manufacturing facilities and ensuring all product labeling and marketing conform to FDA guidelines.
What are the main risks for HCLC?
Health-Chem Corporation faces several significant risks. A primary concern is the extreme liquidity risk associated with its OTC Other tier listing and unknown disclosure status, which can lead to wide bid-ask spreads and difficulty in trading shares. Financially, the company operates with a negative profit margin of -27.9% and a low gross margin of 9.8%, indicating ongoing profitability challenges. The highly negative Beta of -26.02 suggests extreme market volatility. Operationally, the company is subject to intense competition from larger, more resource-rich pharmaceutical firms in the transdermal drug delivery space. Furthermore, the pharmaceutical industry's strict and evolving regulatory environment poses continuous compliance burdens and potential delays for product development and market access. Dependence on a mature product line also necessitates successful diversification or innovation for sustained long-term growth.
What are the key factors to evaluate for HCLC?
Health-Chem Corporation (HCLC) holds an AI score of 38/100 (low). Not financial advice.
How frequently does HCLC data refresh on this page?
HCLC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HCLC's recent stock price performance?
Health-Chem Corporation (HCLC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus and expertise in transdermal drug delivery systems. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HCLC overvalued or undervalued right now?
Valuing Health-Chem Corporation (HCLC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived directly from the provided source data. No external research or estimation was performed. The absence of specific financial figures beyond market cap, margins, and beta limits detailed quantitative analysis. The OTC Other tier and unknown disclosure status significantly restrict available company information.